Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

New special issue on hereditary endocrine tumours published in Endocrine-Related Cancer
The Society for Endocrinology journal,Endocrine-Related Cancer, has recently published a special issue on‘Hereditary endocrine tumours: Current state-of-the-art and research opportunities’. It is guest edited by Steven Waguespack and Constantine Stratakis, and contains eight free-to-read reviews covering topics such as: •New and future perspectives for parathyroid carcinoma•The state of science in medullary thyroid carcinoma: current challenges and unmet needs•Challenges and opportunities in genetic counseling for hereditary endocrine neoplasia syndromes• GPR...
Source: Society for Endocrinology - July 21, 2020 Category: Endocrinology Source Type: news

Cancer-Derived IgG: A Novel Marker in Parathyroid Carcinoma Cancer-Derived IgG: A Novel Marker in Parathyroid Carcinoma
Cancer-derived IgG is a novel biomarker that could play an important role in the differential diagnosis and prognosis prediction of parathyroid carcinoma.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

New tool used to more accurately predict parathyroid cancer return
Researchers at the University of Texas have created a new prognostic tool to predict the risk of recurrence of parathyroid cancer in patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 28, 2017 Category: Consumer Health News Source Type: news

Helpful tool allows physicians to more accurately predict parathyroid cancer recurrence
A newly-created prognostic tool reliably predicts the recurrence of parathyroid cancer, enabling physicians to identify patients at the highest risk. Consequently, the tool also helps to determine the optimum postoperative strategy, including aggressive surveillance and additional treatments, according to study results. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 28, 2017 Category: Science Source Type: news

Helpful tool allows physicians to more accurately predict parathyroid cancer recurrence
(American College of Surgeons) A newly-created prognostic tool reliably predicts the recurrence of parathyroid cancer, enabling physicians to identify patients at the highest risk. Consequently, the tool also helps to determine the optimum postoperative strategy, including aggressive surveillance and additional treatments, according to study results published online as an 'article in press' on the Journal of the American College of Surgeons website ahead of print publication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2017 Category: Global & Universal Source Type: news